• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Counseling Intervention and Cardiovascular Events in People With Peripheral Artery Disease: A Post Hoc Analysis of the BIP Randomized Clinical Trial.有外周动脉疾病患者的咨询干预和心血管事件:BIP 随机临床试验的事后分析。
JAMA Surg. 2024 Nov 1;159(11):1262-1270. doi: 10.1001/jamasurg.2024.3083.
2
Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic peripheral arterial disease.症状性外周动脉疾病患者血管介入成功后额外运动疗法的效果
Cochrane Database Syst Rev. 2024 May 2;5(5):CD014736. doi: 10.1002/14651858.CD014736.pub2.
3
Mobile health technologies to improve walking distance in people with intermittent claudication.移动医疗技术改善间歇性跛行患者的步行距离。
Cochrane Database Syst Rev. 2024 Feb 14;2(2):CD014717. doi: 10.1002/14651858.CD014717.pub2.
4
Exercise for intermittent claudication.间歇性跛行的运动疗法
Cochrane Database Syst Rev. 2017 Dec 26;12(12):CD000990. doi: 10.1002/14651858.CD000990.pub4.
5
Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of cardiovascular diseases.用于心血管疾病一级和二级预防的饮食预防高血压(DASH)方案。
Cochrane Database Syst Rev. 2025 May 6;5(5):CD013729. doi: 10.1002/14651858.CD013729.pub2.
6
Outcomes of specialist physiotherapy for functional motor disorder: the Physio4FMD RCT.功能性运动障碍专科物理治疗的效果:Physio4FMD随机对照试验
Health Technol Assess. 2025 Jul;29(34):1-28. doi: 10.3310/MKAC9495.
7
Smoking cessation for secondary prevention of cardiovascular disease.戒烟对心血管疾病二级预防的作用。
Cochrane Database Syst Rev. 2022 Aug 8;8(8):CD014936. doi: 10.1002/14651858.CD014936.pub2.
8
Cilostazol for intermittent claudication.西洛他唑用于间歇性跛行。
Cochrane Database Syst Rev. 2014 Oct 31;2014(10):CD003748. doi: 10.1002/14651858.CD003748.pub4.
9
Omega-3 fatty acids for intermittent claudication.ω-3 脂肪酸治疗间歇性跛行。
Cochrane Database Syst Rev. 2024 Oct 29;10(10):CD003833. doi: 10.1002/14651858.CD003833.pub5.
10
The Prognostic Potential of Insulin-like Growth Factor-Binding Protein 1 for Cardiovascular Complications in Peripheral Artery Disease.胰岛素样生长因子结合蛋白1对周围动脉疾病心血管并发症的预后评估价值
J Cardiovasc Dev Dis. 2025 Jul 1;12(7):253. doi: 10.3390/jcdd12070253.

引用本文的文献

1
Association between neuroticism, genetic susceptibility, and peripheral artery disease risk: a prospective study in UK Biobank.神经质、遗传易感性与外周动脉疾病风险之间的关联:英国生物银行的一项前瞻性研究。
Eur Arch Psychiatry Clin Neurosci. 2025 Sep 16. doi: 10.1007/s00406-025-02111-y.
2
Depression and Physical Activity in PAD: Addressing the Missing Link.外周动脉疾病中的抑郁与身体活动:解决缺失的环节
J Atheroscler Thromb. 2025 Sep 1;32(9):1098-1100. doi: 10.5551/jat.ED286. Epub 2025 Jun 10.
3
Association of Depression with Walking in People with Peripheral Artery Disease: A Post-Hoc Analysis of the BIP Trial.外周动脉疾病患者中抑郁症与步行的关联:BIP试验的事后分析
J Atheroscler Thromb. 2025 Sep 1;32(9):1101-1108. doi: 10.5551/jat.65531. Epub 2025 Mar 5.

本文引用的文献

1
Psychological Distress and the Risk of Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease.冠心病患者的心理困扰与不良心血管结局风险
JACC Adv. 2024 Feb;3(2). doi: 10.1016/j.jacadv.2023.100794. Epub 2023 Dec 22.
2
Effects of Lifestyle Modification on Psychosocial Function in Patients With Resistant Hypertension: SECONDARY OUTCOMES FROM THE TRIUMPH RANDOMIZED CLINICAL TRIAL.生活方式改变对难治性高血压患者心理社会功能的影响:来自 TRIUMPH 随机临床试验的次要结局。
J Cardiopulm Rehabil Prev. 2024 Jan 1;44(1):64-70. doi: 10.1097/HCR.0000000000000801. Epub 2023 May 24.
3
A Survey of the Opinions of Patients and Health Professionals about Exercise Therapy for Peripheral Artery Disease.患者与健康专业人员对周围动脉疾病运动疗法的意见调查
Eur J Vasc Endovasc Surg. 2023 Jul;66(1):144-145. doi: 10.1016/j.ejvs.2023.04.021. Epub 2023 Apr 21.
4
Effect of Brief Counseling by Allied Health Professionals on Step Count of People With Peripheral Artery Disease: A Randomized Clinical Trial.联合健康专业人员的简短咨询对周围血管疾病患者步数的影响:一项随机临床试验。
JAMA Cardiol. 2023 Apr 1;8(4):394-399. doi: 10.1001/jamacardio.2022.5437.
5
Physical Activity and Risk of Major Diabetes-Related Complications in Individuals With Diabetes: A Systematic Review and Meta-Analysis of Observational Studies.体力活动与糖尿病患者主要糖尿病相关并发症风险的关系:一项观察性研究的系统回顾和荟萃分析。
Diabetes Care. 2022 Dec 1;45(12):3101-3111. doi: 10.2337/dc22-0886.
6
Update on the pathophysiology and medical treatment of peripheral artery disease.外周动脉疾病的病理生理学和医学治疗进展。
Nat Rev Cardiol. 2022 Jul;19(7):456-474. doi: 10.1038/s41569-021-00663-9. Epub 2022 Jan 7.
7
Provision of exercise services in patients with peripheral artery disease in the United Kingdom.英国外周动脉疾病患者的运动服务提供。
Vascular. 2022 Oct;30(5):874-881. doi: 10.1177/17085381211035259. Epub 2021 Aug 4.
8
Network Meta-Analysis Comparing the Outcomes of Treatments for Intermittent Claudication Tested in Randomized Controlled Trials.网络荟萃分析比较随机对照试验中间歇性跛行治疗结果。
J Am Heart Assoc. 2021 May 4;10(9):e019672. doi: 10.1161/JAHA.120.019672. Epub 2021 Apr 23.
9
High ankle brachial index predicts high risk of cardiovascular events amongst people with peripheral artery disease.高踝肱指数预测外周动脉疾病患者心血管事件发生的高风险。
PLoS One. 2020 Nov 12;15(11):e0242228. doi: 10.1371/journal.pone.0242228. eCollection 2020.
10
Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial.健康状况评分与症状性外周动脉疾病患者心血管和肢体结局的相关性:EUCLID(评估替格瑞洛在症状性外周动脉疾病中的应用)试验的见解。
J Am Heart Assoc. 2020 Oct 20;9(19):e016573. doi: 10.1161/JAHA.120.016573. Epub 2020 Sep 13.

有外周动脉疾病患者的咨询干预和心血管事件:BIP 随机临床试验的事后分析。

Counseling Intervention and Cardiovascular Events in People With Peripheral Artery Disease: A Post Hoc Analysis of the BIP Randomized Clinical Trial.

机构信息

Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Australia.

Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville, Australia.

出版信息

JAMA Surg. 2024 Nov 1;159(11):1262-1270. doi: 10.1001/jamasurg.2024.3083.

DOI:10.1001/jamasurg.2024.3083
PMID:39167413
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11339702/
Abstract

IMPORTANCE

It is unclear whether counseling to promote walking reduces the risk of major adverse cardiovascular events (MACE) in people with peripheral artery disease (PAD).

OBJECTIVE

To test whether a counseling intervention designed to increase walking reduced the risk of MACE in patients with PAD.

DESIGN, SETTING, AND PARTICIPANTS: The BIP trial was a randomized clinical trial, with recruitment performed between January 2015 and July 2018 and follow-up concluded in August 2023. Participants with walking impairment due to PAD from vascular departments in the Australian cities of Brisbane, Sydney, and Townsville were randomly allocated 1:1 to the intervention or control group. Data were originally analyzed in March 2024.

INTERVENTION

Four brief counseling sessions aimed to help patients with the challenges of increasing physical activity.

MAIN OUTCOMES AND MEASURES

The primary outcome was the between-group difference in risk of MACE, which included myocardial infarction (MI), stroke, and cardiovascular death. The relationship between Intermittent Claudication Questionnaire (ICQ) scores, PAD Quality of Life (PADQOL) scores, and MACE was examined with Cox proportional hazard regression analyses.

RESULTS

A total of 200 participants were included, with 102 allocated to the counseling intervention (51.0%) and 98 to the control group (49.0%).Participants were followed up for a mean (SD) duration of 3.5 (2.6) years. Median (IQR) participant age was 70 (63-76) years, and 56 of 200 participants (28.0%) were female. A total of 31 individuals had a MACE (composed of 19 MIs, 4 strokes, and 8 cardiovascular deaths). Participants allocated to the intervention were significantly less likely to have a MACE than participants in the control group (10 of 102 participants [9.8%] vs 21 of 98 [21.4%]; hazard ratio [HR], 0.43; 95% CI, 0.20-0.91; P = .03). Greater disease-specific quality of life (QOL) scores at 4 months (ICQ: HR per 1-percentage point increase, 0.97; 95% CI, 0.95-0.99; P < .001; PADQOL factor 3 [symptoms and limitations in physical functioning]: HR per 1-unit increase, 0.91; 95% CI, 0.84-0.98; P = .01) and at 12 months (ICQ: HR per 1-percentage point increase, 0.97; 95% CI, 0.95-0.99; P = .003; PADQOL factor 3: HR per 1-unit increase, 0.91; 95% CI, 0.84-0.98; P = .02) were associated with a lower risk of MACE. In analyses adjusted for ICQ or PADQOL factor 3 scores at either 4 or 12 months, allocation to the counseling intervention was no longer significantly associated with a lower risk of MACE.

CONCLUSIONS AND RELEVANCE

This post hoc exploratory analysis of the BIP randomized clinical trial suggested that the brief counseling intervention designed to increase walking may reduce the risk of MACE, possibly due to improvement in QOL.

TRIAL REGISTRATION

anzctr.org.au Identifier: ACTRN12614000592640.

摘要

重要性

目前尚不清楚针对促进步行的咨询是否可以降低外周动脉疾病 (PAD) 患者发生主要不良心血管事件 (MACE) 的风险。

目的

检验旨在增加步行的咨询干预是否可以降低 PAD 患者的 MACE 风险。

设计、地点和参与者:BIP 试验是一项随机临床试验,于 2015 年 1 月至 2018 年 7 月期间招募参与者,并于 2023 年 8 月结束随访。来自澳大利亚布里斯班、悉尼和汤斯维尔血管科的因 PAD 而导致行走能力受损的患者被随机分配至干预组或对照组,比例为 1:1。原始数据分析于 2024 年 3 月进行。

干预

共进行了 4 次简短的咨询会议,旨在帮助患者应对增加身体活动的挑战。

主要结果和测量指标

主要结局是干预组与对照组之间 MACE 风险的差异,包括心肌梗死 (MI)、中风和心血管死亡。使用 Cox 比例风险回归分析检查了间歇性跛行问卷 (ICQ) 评分、PAD 生活质量 (PADQOL) 评分与 MACE 之间的关系。

结果

共纳入 200 名参与者,其中 102 名被分配至咨询干预组(51.0%),98 名被分配至对照组(49.0%)。参与者的平均(SD)随访时间为 3.5(2.6)年。参与者的中位(IQR)年龄为 70(63-76)岁,200 名参与者中有 56 名(28.0%)为女性。共有 31 人发生 MACE(由 19 例 MI、4 例中风和 8 例心血管死亡组成)。与对照组相比,接受干预的参与者发生 MACE 的可能性显著降低(102 名参与者中有 10 名 [9.8%] vs 98 名参与者中有 21 名 [21.4%];风险比 [HR],0.43;95%CI,0.20-0.91;P=0.03)。4 个月时疾病特异性生活质量 (QOL) 评分更高(ICQ:每增加 1 个百分点的 HR,0.97;95%CI,0.95-0.99;P<0.001;PADQOL 因子 3 [症状和身体功能受限]:每增加 1 个单位的 HR,0.91;95%CI,0.84-0.98;P=0.01)和 12 个月时更高(ICQ:每增加 1 个百分点的 HR,0.97;95%CI,0.95-0.99;P=0.003;PADQOL 因子 3:每增加 1 个单位的 HR,0.91;95%CI,0.84-0.98;P=0.02)与 MACE 风险降低相关。在调整了 4 个月或 12 个月时的 ICQ 或 PADQOL 因子 3 评分后的分析中,咨询干预的分配与 MACE 风险降低不再显著相关。

结论和相关性

本项对 BIP 随机临床试验的事后探索性分析表明,旨在增加步行的简短咨询干预可能会降低 MACE 的风险,这可能是由于 QOL 的改善所致。

试验注册

anzctr.org.au Identifier:ACTRN12614000592640。